JP2021513328A - 抗ms4a6a抗体及びその使用方法 - Google Patents
抗ms4a6a抗体及びその使用方法 Download PDFInfo
- Publication number
- JP2021513328A JP2021513328A JP2020541758A JP2020541758A JP2021513328A JP 2021513328 A JP2021513328 A JP 2021513328A JP 2020541758 A JP2020541758 A JP 2020541758A JP 2020541758 A JP2020541758 A JP 2020541758A JP 2021513328 A JP2021513328 A JP 2021513328A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ms4a6a
- amino acid
- disease
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023095282A JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ms4a6a抗体及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624578P | 2018-01-31 | 2018-01-31 | |
| US62/624,578 | 2018-01-31 | ||
| US201862646846P | 2018-03-22 | 2018-03-22 | |
| US62/646,846 | 2018-03-22 | ||
| PCT/US2019/016141 WO2019152706A1 (en) | 2018-01-31 | 2019-01-31 | Anti-ms4a6a antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095282A Division JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ms4a6a抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513328A true JP2021513328A (ja) | 2021-05-27 |
| JP2021513328A5 JP2021513328A5 (cg-RX-API-DMAC7.html) | 2022-02-07 |
Family
ID=67479397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541758A Pending JP2021513328A (ja) | 2018-01-31 | 2019-01-31 | 抗ms4a6a抗体及びその使用方法 |
| JP2023095282A Pending JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ms4a6a抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095282A Pending JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ms4a6a抗体及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20210122817A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3746484A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021513328A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112204050B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019152706A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
| EP3746484A4 (en) | 2018-01-31 | 2021-11-17 | Alector LLC | ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF |
| PH12022550239A1 (en) | 2019-07-31 | 2022-12-19 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CN115029383B (zh) * | 2022-04-21 | 2024-02-20 | 苏天生命科技(苏州)有限公司 | Ms4a3蛋白在调控红细胞成熟中的应用 |
| CN116219009B (zh) * | 2022-10-19 | 2024-10-01 | 杭州师范大学 | 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用 |
| AU2024370996A1 (en) * | 2023-10-30 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008506637A (ja) * | 2004-06-14 | 2008-03-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 胎児起源の細胞に対する抗体 |
| JP2013534411A (ja) * | 2010-05-25 | 2013-09-05 | サノフイ | 疼痛に関与する化合物の同定に関する方法および使用、ならびに痛覚過敏の診断方法 |
| CN105969901A (zh) * | 2016-07-27 | 2016-09-28 | 北京泱深生物信息技术有限公司 | Ms4a6a作为多发性骨髓瘤诊治标志物的用途 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002251692A1 (en) | 2000-12-08 | 2002-08-19 | Duke University | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| GB0125338D0 (en) | 2001-10-22 | 2001-12-12 | Isis Innovation | Process for reducing immunogenic reactions using selective TH1 cell binding antibodies |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| GB0324888D0 (en) | 2003-10-24 | 2003-11-26 | Novartis Ag | Organic compounds |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN101001879A (zh) | 2004-06-14 | 2007-07-18 | 伊利诺伊大学董事会 | 与胎儿而非成体cd34+/cd36+细胞结合的抗体 |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2108701A1 (en) | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| CN104774264B (zh) * | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20190321443A1 (en) * | 2016-02-16 | 2019-10-24 | President And Fellows Of Harvard College | Modulators of MS4A activity |
| CN105759057A (zh) * | 2016-04-12 | 2016-07-13 | 上海凯璟生物科技有限公司 | 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法 |
| EP3746484A4 (en) | 2018-01-31 | 2021-11-17 | Alector LLC | ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF |
| EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
| US20220133808A1 (en) | 2019-02-01 | 2022-05-05 | Avrobio, Inc. | Compositions and methods for treating neurocognitive disorders |
| PH12022550239A1 (en) | 2019-07-31 | 2022-12-19 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| CN114599393A (zh) | 2019-10-22 | 2022-06-07 | 比奥根Ma公司 | 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体 |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
-
2019
- 2019-01-31 EP EP19747384.6A patent/EP3746484A4/en active Pending
- 2019-01-31 CN CN201980018630.2A patent/CN112204050B/zh active Active
- 2019-01-31 US US16/965,675 patent/US20210122817A1/en not_active Abandoned
- 2019-01-31 JP JP2020541758A patent/JP2021513328A/ja active Pending
- 2019-01-31 WO PCT/US2019/016141 patent/WO2019152706A1/en not_active Ceased
-
2022
- 2022-04-18 US US17/722,624 patent/US12215149B2/en active Active
-
2023
- 2023-06-09 JP JP2023095282A patent/JP2023113896A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008506637A (ja) * | 2004-06-14 | 2008-03-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 胎児起源の細胞に対する抗体 |
| JP2013534411A (ja) * | 2010-05-25 | 2013-09-05 | サノフイ | 疼痛に関与する化合物の同定に関する方法および使用、ならびに痛覚過敏の診断方法 |
| CN105969901A (zh) * | 2016-07-27 | 2016-09-28 | 北京泱深生物信息技术有限公司 | Ms4a6a作为多发性骨髓瘤诊治标志物的用途 |
Non-Patent Citations (1)
| Title |
|---|
| "抗体医薬の現状と課題", 科学技術動向, vol. 10月号, JPN6022055226, 2009, pages 13 - 25, ISSN: 0005130153 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023113896A (ja) | 2023-08-16 |
| WO2019152706A1 (en) | 2019-08-08 |
| US20220380455A1 (en) | 2022-12-01 |
| US20210122817A1 (en) | 2021-04-29 |
| US12215149B2 (en) | 2025-02-04 |
| EP3746484A1 (en) | 2020-12-09 |
| CN112204050A (zh) | 2021-01-08 |
| EP3746484A4 (en) | 2021-11-17 |
| CN112204050B (zh) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7486636B2 (ja) | 抗ms4a4a抗体及びその使用方法 | |
| US12215149B2 (en) | Anti-MS4A6A antibodies and methods of use thereof | |
| JP7612658B2 (ja) | 抗ms4a4a抗体、及びその使用方法 | |
| KR20210015872A (ko) | 항-sirpa 항체 및 그의 사용 방법 | |
| CN112912144A (zh) | 抗cd33抗体及其使用方法 | |
| JP2021508498A (ja) | 抗tmem106b抗体及びその使用方法 | |
| JP2023519962A (ja) | 抗mertk抗体及びその使用方法 | |
| WO2023010076A1 (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| US20240174746A1 (en) | Anti-tmem106b antibodies and methods of use thereof | |
| HK40036037A (en) | Anti-ms4a6a antibodies and methods of use thereof | |
| HK40034438A (zh) | 抗ms4a4a抗体及其使用方法 | |
| HK40059921A (zh) | 抗cd33抗体及其使用方法 | |
| HK40063237A (en) | Anti-ms4a4a antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201026 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201005 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230307 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230816 |